Eagle Pharmaceuticals (NASDAQ:EGRX) Coverage Initiated at StockNews.com

Stock analysts at StockNews.com initiated coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a research note issued on Thursday. The firm set a “hold” rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Stock Performance

Shares of NASDAQ:EGRX opened at $3.95 on Thursday. The firm has a market capitalization of $51.30 million, a P/E ratio of 3.35 and a beta of 0.53. The stock has a 50 day moving average price of $4.50 and a 200-day moving average price of $4.66. Eagle Pharmaceuticals has a 52-week low of $3.21 and a 52-week high of $15.91.

Institutional Trading of Eagle Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Cubist Systematic Strategies LLC bought a new stake in shares of Eagle Pharmaceuticals in the 2nd quarter worth approximately $145,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in Eagle Pharmaceuticals during the second quarter valued at $65,000. Perceptive Advisors LLC purchased a new position in Eagle Pharmaceuticals during the second quarter valued at $971,000. Mackenzie Financial Corp bought a new stake in Eagle Pharmaceuticals in the second quarter worth $60,000. Finally, Fidelis Capital Partners LLC purchased a new stake in shares of Eagle Pharmaceuticals in the second quarter worth $71,000. 85.36% of the stock is owned by hedge funds and other institutional investors.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.